Interleukin-6 and the network of several cytokines in multiple myeloma: An overview of clinical and experimental data

被引:76
作者
Lauta, VM
机构
[1] Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School--Policlinico, 70124, Bari
关键词
interleukin-6; cytokines; multiple myeloma;
D O I
10.1006/cyto.2001.0982
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Study of the network of cytokines has helped identify cell growth factors in multiple myeloma. Plasma cells themselves may produce autocrine interleukin 6 (IL-6) while IL-6 production by bone marrow stromal cells may operate a paracrine mechanism. Involvement of IL-6 in multiple myeloma is indicated by its ability to induce the differentiation of myeloma plasmablasts into mature malignant plasma cells. Differential diagnosis between multiple myeloma and monoclonal gammopathies of undetermined significance (MGUS) is generally based on clinical and laboratory parameters. Nevertheless, evaluation of the serum level of IL-6, C reactive protein, soluble IL-6 receptor, soluble IL-2 receptor together with the activity exerted by IL-3 and IL-4 on some cellular subsets constitutes an additional element in the differential diagnosis of border-line cases. Serum levels of IL-6, soluble IL-6 receptor (sIL-6R), soluble interleukin-2 receptor (sIL-2R) and the expression of membrane-bound IL-2 receptors, both on bone marrow plasma cells and on peripheral blood mononuclear cells are correlated with disease activity and disease stage. In addition, IL-6 and sIL-6R serum levels correlate with the duration of survival, as high values at the time of diagnosis correlate with short duration of survival. (C) 2001 Academic Press.
引用
收藏
页码:79 / 86
页数:8
相关论文
共 78 条
[71]   MOUSE PLASMACYTOMA GROWTH-INVIVO - ENHANCEMENT BY INTERLEUKIN-6 (IL-6) AND INHIBITION BY ANTIBODIES DIRECTED AGAINST IL-6 OR ITS RECEPTOR [J].
VINK, A ;
COULIE, P ;
WARNIER, G ;
RENAULD, JC ;
STEVENS, M ;
DONCKERS, D ;
VANSNICK, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (03) :997-1000
[72]   GLUCOCORTICOIDS INHIBIT THE PRODUCTION OF IL-6 FROM MONOCYTES, ENDOTHELIAL-CELLS AND FIBROBLASTS [J].
WAAGE, A ;
SLUPPHAUG, G ;
SHALABY, R .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (11) :2439-2443
[73]  
Westendorf JJ, 1996, LEUKEMIA, V10, P866
[74]   INTERFERON ALFA-2B VERSUS NO MAINTENANCE THERAPY DURING THE PLATEAU-PHASE IN MULTIPLE-MYELOMA - A RANDOMIZED STUDY [J].
WESTIN, J ;
RODJER, S ;
TURESSON, I ;
CORTELEZZI, A ;
HJORTH, M ;
ZADOR, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (03) :561-568
[75]  
Woo EY, 2001, CANCER RES, V61, P4766
[76]   A role for TGF-β in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood [J].
Yamagiwa, S ;
Gray, JD ;
Hashimoto, S ;
Horwitz, DA .
JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7282-7289
[77]   Novel CD28-responsive enhancer activated by CREB/ATF and AP-1 families in the human interleukin-2 receptor α-chain locus [J].
Yeh, JH ;
Lecine, P ;
Nunes, JA ;
Spicuglia, S ;
Ferrier, P ;
Olive, D ;
Imbert, J .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (14) :4515-4527
[78]  
YOSHIAKI O, 1991, LEUKEMIA, V5, P585